BNT162b2 XBB疫苗对XBB和JN.1亚谱系的有效性。
Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages.
作者信息
Tartof Sara Y, Slezak Jeff M, Puzniak Laura, Frankland Timothy B, Ackerson Bradley K, Jodar Luis, McLaughlin John M
机构信息
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Global Vaccines and Antivirals, Pfizer Inc, Collegeville, Pennsylvania, USA.
出版信息
Open Forum Infect Dis. 2024 Jul 1;11(7):ofae370. doi: 10.1093/ofid/ofae370. eCollection 2024 Jul.
We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sublineages.
我们提供了之前在南加州凯撒医疗集团进行的检测阴性病例对照研究的最新结果（2023年10月11日至2024年2月29日），以评估BNT162b2 XBB1.5适配疫苗针对特定亚谱系的有效性。结果表明，与XBB亚谱系相比，XBB1.5适配疫苗对JN.1的有效性可能降低。
Zotero 插件